VIDEO: Chemo plus targeted therapy improves response in BRAF V600E-mutant metastatic CRC
In this video, Michael Cecchini, MD, discusses the significance of results from the phase 3 BREAKWATER trial, which were presented at ASCO Gastrointestinal Cancers Symposium.
The open-label, global, randomized trial evaluated first-line encorafenib (Braftovi, Pfizer) plus cetuximab (Erbitux, Lilly) with or without chemotherapy vs. standard of care in untreated BRAF V600E-mutant metastatic colorectal cancer.
Results showed patients in the encorafenib/cetuximab plus FOLFOX arm had statistically significant improvement in objective response rate compared with those in the standard-of-care arm (60.9% vs. 40%).
“We saw some overall survival data presented, which was promising, but not technically statistically significant,” Cecchini, associate professor of medical oncology at Yale School of Medicine, said. “Again, this was an early look with very strict cutoff in terms of the statistical design about what would be called significant vs. not. But based on the PFS and the overall response rate, this study is thus far positive.”
Reference:
- Kopetz S, et al. Abstract 16. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
Collapse
Read more about